Cargando…
Advances in the diagnosis and early management of gestational trophoblastic disease
Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978730/ https://www.ncbi.nlm.nih.gov/pubmed/36936581 http://dx.doi.org/10.1136/bmjmed-2022-000321 |
_version_ | 1784899581578838016 |
---|---|
author | Joyce, Caroline M Fitzgerald, Brendan McCarthy, Tommie V Coulter, John O'Donoghue, Keelin |
author_facet | Joyce, Caroline M Fitzgerald, Brendan McCarthy, Tommie V Coulter, John O'Donoghue, Keelin |
author_sort | Joyce, Caroline M |
collection | PubMed |
description | Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing two copies of the paternal genome, which is classified as partial when the maternal genome is present or complete when the maternal genome is absent. Hydatidiform mole typically presents in the first trimester with irregular vaginal bleeding and can be suspected on ultrasound but confirmation requires histopathological evaluation of the products of conception. Most molar pregnancies resolve without treatment after uterine evacuation, but occasionally the disease persists and develops into gestational trophoblastic neoplasia. Close monitoring of women after molar pregnancy, with regular measurement of human chorionic gonadotrophin concentrations, allows for early detection of malignancy. Given the rarity of the disease, clinical management and treatment is best provided in specialist centres where very high cure rates are achievable. This review looks at advances in the diagnosis and early management of gestational trophoblastic disease and highlights updates to disease classification and clinical guidelines. Use of molecular genotyping for improved diagnostic accuracy and risk stratification is reviewed and future biomarkers for the earlier detection of malignancy are considered. |
format | Online Article Text |
id | pubmed-9978730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-99787302023-03-16 Advances in the diagnosis and early management of gestational trophoblastic disease Joyce, Caroline M Fitzgerald, Brendan McCarthy, Tommie V Coulter, John O'Donoghue, Keelin BMJ Med Review Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing two copies of the paternal genome, which is classified as partial when the maternal genome is present or complete when the maternal genome is absent. Hydatidiform mole typically presents in the first trimester with irregular vaginal bleeding and can be suspected on ultrasound but confirmation requires histopathological evaluation of the products of conception. Most molar pregnancies resolve without treatment after uterine evacuation, but occasionally the disease persists and develops into gestational trophoblastic neoplasia. Close monitoring of women after molar pregnancy, with regular measurement of human chorionic gonadotrophin concentrations, allows for early detection of malignancy. Given the rarity of the disease, clinical management and treatment is best provided in specialist centres where very high cure rates are achievable. This review looks at advances in the diagnosis and early management of gestational trophoblastic disease and highlights updates to disease classification and clinical guidelines. Use of molecular genotyping for improved diagnostic accuracy and risk stratification is reviewed and future biomarkers for the earlier detection of malignancy are considered. BMJ Publishing Group 2022-12-16 /pmc/articles/PMC9978730/ /pubmed/36936581 http://dx.doi.org/10.1136/bmjmed-2022-000321 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Joyce, Caroline M Fitzgerald, Brendan McCarthy, Tommie V Coulter, John O'Donoghue, Keelin Advances in the diagnosis and early management of gestational trophoblastic disease |
title | Advances in the diagnosis and early management of gestational trophoblastic disease |
title_full | Advances in the diagnosis and early management of gestational trophoblastic disease |
title_fullStr | Advances in the diagnosis and early management of gestational trophoblastic disease |
title_full_unstemmed | Advances in the diagnosis and early management of gestational trophoblastic disease |
title_short | Advances in the diagnosis and early management of gestational trophoblastic disease |
title_sort | advances in the diagnosis and early management of gestational trophoblastic disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978730/ https://www.ncbi.nlm.nih.gov/pubmed/36936581 http://dx.doi.org/10.1136/bmjmed-2022-000321 |
work_keys_str_mv | AT joycecarolinem advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease AT fitzgeraldbrendan advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease AT mccarthytommiev advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease AT coulterjohn advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease AT odonoghuekeelin advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease |